• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Kidron Nadav

    3/18/26 7:04:07 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care
    Get the next $DRTS alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    KIDRON NADAV

    (Last)(First)(Middle)
    20 MAMILLA

    (Street)
    JERUSALEM

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Alpha Tau Medical Ltd. [ DRTS ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Ordinary Shares2,986D
    Restricted Share Units(1)7,767D
    Restricted Share Units(2)4,680D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Options(3)06/12/202505/19/2035Ordinary Shares35,554$2.79D
    Options(4) (4)03/09/2036Ordinary Shares15,527$6.41D
    Explanation of Responses:
    1. These ordinary shares represent the unvested portion of a grant of restricted share units, which vests in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
    2. These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
    3. These are options to acquire ordinary shares, which options will vest in monthly equal installments for a period of three years commencing May 12, 2025, subject to the Reporting Person's continued service.
    4. These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
    /s/ Nadav Kidron03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $DRTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRTS

    DatePrice TargetRatingAnalyst
    3/4/2026$5.00Overweight → Neutral
    Piper Sandler
    12/15/2023$8.00Buy
    Citigroup
    4/24/2023$9.00Buy
    H.C. Wainwright
    4/14/2022$20.00Overweight
    Cantor Fitzgerald
    4/8/2022$19.00Overweight
    Piper Sandler
    4/4/2022$21.00Buy
    Citigroup
    More analyst ratings

    $DRTS
    SEC Filings

    View All

    SEC Form S-8 filed by Alpha Tau Medical Ltd.

    S-8 - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 5:01:21 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 20-F filed by Alpha Tau Medical Ltd.

    20-F - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 4:03:11 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    3/9/26 4:03:17 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alpha Tau downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Alpha Tau from Overweight to Neutral and set a new price target of $5.00

    3/4/26 8:30:52 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on Alpha Tau with a new price target

    Citigroup initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $8.00

    12/15/23 8:07:49 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Alpha Tau with a new price target

    H.C. Wainwright initiated coverage of Alpha Tau with a rating of Buy and set a new price target of $9.00

    4/24/23 7:44:43 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Avruch Michael

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:04:47 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Kidron Nadav

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:04:07 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Sofer Uzi

    3 - Alpha Tau Medical Ltd. (0001871321) (Issuer)

    3/18/26 7:03:38 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau to Present at Sidoti March Virtual Small Cap Conference

    JERUSALEM, March 16, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that CFO Raphi Levy will present at the Sidoti Virtual Small Cap Conference taking place on March 18-19, 2026. Event:Sidoti Virtual Small Cap ConferenceFormat:Company PresentationDate:March 18, 2026Time:10:00 – 10:30AM ETLocation:Virtual Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule. About Alpha Tau Medical Ltd.  Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, de

    3/16/26 10:02:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update

    - Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and the first brain cancer treatment - - Multiple meaningful milestones targeted in the coming months, including completion of patient recruitment in the U.S. pivotal ReSTART skin cancer trial, in the U.S. pilot IMPACT pancreatic cancer trial, and in the U.S. recurrent glioblastoma multiforme feasibility trial - - $76.9 million in cash, cash equivalents & deposits provides continued balance sheet strength for clinical advancement and commercial preparation - JERUSALEM, March 09, 2026 (GLOBE NE

    3/9/26 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer

    - Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clinical societies - JERUSALEM, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that Japan's Ministry of Health, Labour and Welfare ("MHLW") has granted regulatory (Shonin) marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally

    2/24/26 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $DRTS
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors

    JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., ("Oramed"), has been appointed to the Company's Board of Directors ("Board"). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed. "Nadav is a fantastic addition to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "He has spent many years in a position much like ours, at the helm of a public compa

    5/12/25 4:01:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update

    - Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safety profile - - Systemic ORR and complete response rates meaningfully higher thus far than historical Keytruda® monotherapy data in interim read out of a combination trial of Alpha DaRT and Keytruda in treating recurrent unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) - - Interim data from pancreatic cancer trials presented at the prestigious 2025 ASCO GI Symposium - - FDA approval of Investigational Device Exemption (IDE) and IDE supplement t

    3/12/25 4:02:00 PM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

    JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that following its Annual General Meeting of Company shareholders in Jerusalem, Ms. Maya Netser has been appointed to the Company's Board of Directors ("Board"). Mr. Meir Jakobsohn is completing his term on the Board, having decided not to pursue re-election, but will continue to serve the Company in an advisory capacity. "I am delighted to welcome Maya to the Board," said Company CEO and Chairman of the Board Mr. Uzi Sofer. "Maya brings a wealth of experience and a keen under

    12/17/24 9:00:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care